GAMMA Investing LLC Boosts Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

GAMMA Investing LLC increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 897.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,795 shares of the company’s stock after purchasing an additional 7,913 shares during the quarter. GAMMA Investing LLC’s holdings in Replimune Group were worth $902,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in REPL. Sterling Capital Management LLC lifted its holdings in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after buying an additional 1,655 shares in the last quarter. Graham Capital Management L.P. raised its position in Replimune Group by 6.1% in the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock worth $365,000 after purchasing an additional 1,731 shares during the period. MetLife Investment Management LLC boosted its holdings in Replimune Group by 7.2% during the 4th quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock valued at $456,000 after acquiring an additional 2,525 shares during the period. Algert Global LLC raised its holdings in Replimune Group by 7.1% during the 4th quarter. Algert Global LLC now owns 45,820 shares of the company’s stock valued at $555,000 after buying an additional 3,057 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Replimune Group by 33.8% in the fourth quarter. ProShare Advisors LLC now owns 20,788 shares of the company’s stock worth $252,000 after purchasing an additional 5,247 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Up 0.5%

Shares of NASDAQ:REPL opened at $9.83 on Tuesday. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The business has a 50 day moving average of $8.66 and a two-hundred day moving average of $10.86. Replimune Group, Inc. has a 12-month low of $6.44 and a 12-month high of $17.00. The company has a market capitalization of $757.77 million, a PE ratio of -3.20 and a beta of 0.63.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the business posted ($0.25) earnings per share. As a group, analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Insider Activity at Replimune Group

In other news, Director Philip Astley-Sparke sold 32,279 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the sale, the director now directly owns 1,405,071 shares of the company’s stock, valued at approximately $11,324,872.26. This represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Andrew Schwendenman sold 3,287 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $26,460.35. Following the transaction, the chief accounting officer now owns 68,284 shares in the company, valued at $549,686.20. The trade was a 4.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Piper Sandler increased their price objective on Replimune Group from $14.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, June 2nd. JPMorgan Chase & Co. raised their target price on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Replimune Group has a consensus rating of “Buy” and an average target price of $20.83.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.